Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(66), 2022
DOI: 10.1128/aac.01584-21
Links
Tools
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
Journal article published in 2022 by
M. Farouk Chughlay,
Karen I. Barnes 
,
Myriam El Gaaloul,
Nada Abla,
Jörg J. Möhrle ,
Paul Griffin,
Paul van Giersbergen,
Stephanie E. Reuter ,
Hayley B. Schultz,
Anita Kress,
Peter Tapley,
Rebecca A. Webster,
Timothy Wells,
James S. McCarthy,
Bridget E. Barber
and other authors.
,
Myriam El Gaaloul,
Nada Abla,
Jörg J. Möhrle ,
Paul Griffin,
Paul van Giersbergen,
Stephanie E. Reuter ,
Hayley B. Schultz,
Anita Kress,
Peter Tapley,
Rebecca A. Webster,
Timothy Wells,
James S. McCarthy,
Bridget E. Barber
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy.